Compare CGAU & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CGAU | AMRX |
|---|---|---|
| Founded | 2002 | 2002 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.0B |
| IPO Year | 2021 | 2018 |
| Metric | CGAU | AMRX |
|---|---|---|
| Price | $16.02 | $16.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $16.67 | $15.60 |
| AVG Volume (30 Days) | 1.4M | ★ 1.9M |
| Earning Date | 04-29-2026 | 05-01-2026 |
| Dividend Yield | ★ 1.16% | N/A |
| EPS Growth | N/A | ★ 157.89 |
| EPS | N/A | ★ 0.19 |
| Revenue | N/A | N/A |
| Revenue This Year | $25.17 | $4.48 |
| Revenue Next Year | $13.62 | $7.13 |
| P/E Ratio | ★ $11.74 | $84.79 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.71 | $7.67 |
| 52 Week High | $21.17 | $16.61 |
| Indicator | CGAU | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.96 | 79.21 |
| Support Level | $15.07 | $12.46 |
| Resistance Level | $19.95 | N/A |
| Average True Range (ATR) | 0.78 | 0.60 |
| MACD | 0.10 | 0.19 |
| Stochastic Oscillator | 37.80 | 95.99 |
Centerra Gold Inc is principally focused on operating, developing, exploring and acquiring gold and copper properties in North America, Turkey, and other markets world-wide. The company reportable operating segments are Oksut; Mount Milligan; and Molybdenum. It derives maximum revenue from Mount Milligan segment. Geographically, it operates in Turkey, United States, and Canada.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.